MedPageToday -- CHICAGO -- More than half of Medicare patients prescribed a biologic for age-related macular degeneration (AMD) are getting bevacizumab (Avastin) off-label rather than ranibizumab (Lucentis), which is approved for the condition, researchers said here.
